Devices

FDA Clears Median’s AI Lung Cancer Screener

FDA has cleared a Median Technologies 510(k) for eyonis LCS, the first artificial intelligence (AI)–based device cleared for both detection and diagnosis in lung cancer screening. The software-as-a-medical-device is designed to help clinicians identify lung cancer at earlier, potentially curable stages while reducing false positives and unnecessary follow-up procedures, according to the company.

Median says the device analyzes low-dose CT (LDCT) scans to detect and characterize parenchymal pulmonary nodules. In performance testing, eyonis LCS demonstrated 93.3% sensitivity, 92.4% specificity, and a 99.9% negative predictive value, indicating a very low rate of false positives. Median Technologies says this capability could improve diagnostic confidence, reduce inter-reader variability, and streamline screening programs nationwide.

Lung cancer remains the leading cause of cancer death in the U.S., with early-stage detection dramatically improving long-term survival, the company says.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome